Safe Harbor Statement

Transcription

1

2 Safe Harbor Statement This presentation may contain forward-looking statements as defined in the Private Securities Litigation Reform Act of These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the Company s expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 to the Company s Annual Report on Form 10-K for the fiscal year ended January 3, Copies of this Form 10-K, as well as subsequent filings, are available online at or on request from the Company. The Company does not undertake to update any forward-looking statements as a result of new information or future events or developments.

3 Alex Gorsky Worldwide Chairman Medical Devices & Diagnostics

4 In The Past Two Years, We Strengthened core businesses Expanded into new, high-growth businesses Generated $1.8 billion in operational sales growth Invested $3.6 billion in R&D Completed $2.7 billion in strategic acquisitions Grew sales significantly in emerging markets Expanded operating margins by more than 4 points* Grew to become 38% of Johnson & Johnson total 2009 sales and 43% of total operating profit* Very Pleased But Never Satisfied * Excluding special items All figures are for the two-year period

5 We Participate in a Large Majority of the $350B MD&D Market Total WW MD&D Market 2009 Overall MD&D Market CAGR ( ) 5.0% O.U.S. 53% 47% U.S. Non-Johnson & Johnson Markets CAGR for Johnson & Johnson MD&D Markets ( ) 6.1% 38% 62% Johnson & Johnson Markets Market Segments listed above do not include certain minor categories such as Patients Aids & Home, Non Electrical Diagnostics and other minor markets Source: HRI, Internal Estimates

6 Many of Our Markets Are Expected to Grow Faster Than the Overall Market WW MARKET CAGR Advanced Energy +13% Electrophysiology +13% Insulin Delivery +13% Trauma & Extremities +11% Biosurgicals +10% Ear, Nose & Throat +9% Infection Prevention +9% Hernia Repair +9% Aesthetics +9% Women s Health +9% Sports Medicine +8% Obesity +7% Spine +7% OVERALL JOHNSON & JOHNSON MD&D MARKETS +6% OVERALL MD&D MARKET +5% Source: HRI, Internal Estimates Note: All figures operational

7 Many of Our Markets Are Recovering Market Growth 30% 20% Hips Clinical Labs Sutures (U.S.) Electrophysiology 10% 0% -10% 2Q08 3Q08 4Q08 1Q09 2Q09 3Q09 4Q09 1Q10 Internal Estimates

8 Rapidly Evolving Industry Dynamics Favoring Johnson & Johnson Headwinds Demographics/aging population Significant unmet needs/earlier intervention Global expansion/emerging markets Patient influence and involvement Gradual economic recovery Increased access to healthcare Advancing science and technology MD&D Macro-economic challenges Evolving regulatory requirements Multi-stakeholder influence Legal/political environment Changing competitive landscape Tailwinds

9 Johnson & Johnson: World s Largest, Strongest MD&D Business Strong track record of performance Leadership positions (#1 or #2) in key segments Compete in large, attractive categories Global capabilities and advantages of scale, especially in emerging markets Unique understanding of chronic disease states Depth and breadth of Johnson & Johnson 7

10 Seven Extraordinary Franchises Diabetes Care

11 Focused on Treating Many of the World s Most Prevalent Diseases DISEASE/CONDITION Presbyopia Obesity Cardiovascular Disease Diabetes WW PREVALENCE 1.2 billion 425 million 300 million 285 million Source: HRI, Internal Estimates, Archives of Ophthalmology (Dec. 2008)

12 MD&D Sales & Growth Rates 1Q 2010 Total Sales: $6.2 Billion Ops Growth Rate: 8.1% ( : 6.0%) $ U.S. Billions DePuy : 8.3% Ethicon Endo-Surgery : 8.6% Diabetes Care : 6.5% $1.5 +8% $ % $0.6 +6% $ % $0.5 +9% $0.7 +7% $0.7 (3%) Ethicon : 6.6% Cordis : (3.9%) Vision Care : 9.4% Ortho Clinical Diagnostics : 7.7%

13 Strategic Framework Our Credo Broadly Based in Human Health Care Managed for the Long Term Operating Model Decentralized Management Approach Focused on People and Values Growth Innovative Products Robust Pipelines Global Presence Talented People

14 Grow Current Platforms With Innovative Products Sustain/gain share in core businesses Knees, Hips, Spine, Endoscopy, Sutures, SMBG, Contact Lenses, Clinical Labs Each of these businesses generated over $1 billion in 2009 sales; three generated over $2 billion

15 Grow Current Platforms With Innovative Products Grow markets and share in high-growth businesses Electrophysiology, Biosurgicals, Energy Each of these businesses grew at double-digit rates in 2009

16 Grow Current Platforms With Innovative Products Capitalize on new product launches 1 DAY ACUVUE TruEye OneTouch Verio SecureStrap CARTO 3 VITROS 3600 System and 5600 Systems

17 Accelerate and Sustain a Robust Pipeline Advance key internal R&D programs NEVO Sirolimus-Eluting Coronary Stent Pinnacle CoMplete Acetabular Cup System SEDASYS System Fibrin Pad Drug/Lens Combination Product Convergence increasingly important Applying diagnostics expertise across Johnson & Johnson

18 Accelerate and Sustain a Robust Pipeline Optimize the portfolio Strengthen portfolio via acquisitions 2008/09: Mentor, Omrix, SurgRx 2009/10: Acclarent, Finsbury, Gloster Europe Exit non-core businesses, enabling greater focus Professional Wound Care, Independence Technology, Breast Care

19 Strengthen Portfolio Via Acquisitions Less invasive surgical solutions to treat ear, nose and throat conditions An unparalleled range of hip solutions New decontamination technologies to help prevent healthcare-associated infections

20 MD&D Pipeline Highlights Cordis, DePuy, Diabetes Care Pending Approved/Cleared Planned Submissions Planned Submissions Planned Submissions Cordis NEVO Coronary Stent (CE Mark) EXOSEAL VCD (PMA) CARTO Xpress Navigation Technology (510(k)) CARTO 3 Navigation Technology (Japan & China) THERMOCOOL SF Irrigated Catheter (PMA) CYPHER Coronary Stent 4.0 (PMA) CYPHER Xtend Extended Dating (PMA Supp) THERMOCOOL SMARTTouch Contact Force Catheter (CE Mark) DePuy CoMplete Acetabular Hip System GRIPTION TF (TIFOAM)* Hip and Knee AOX Poly for Sigma and LCS Affixus Hip Fracture Nail* MEDSTREAM * Programmable Pump Diabetes Care Diabetes High Accuracy Blood Glucose System Version 1 Cordis CYPHER Coronary Stent 2.25 (PMA Supp) EXOSEAL VCD (CE Mark) CARTO 3 Navigation Technology (510(k) & CE Mark) CARTO 3 Diagnostics Catheter Portfolio (510(k) & CE Mark) NAVISTAR THERMOCOOL Afib Indication (PMA) THERMOCOOL SF Irrigated Catheter (CE Mark) PRESILLION Plus Bare Metal Stent (CE Mark) CYPHER SELECT Plus Stent (Japan) DePuy ASPHERE * Contoured Metal Heads TRUMATCH * Personalized Solutions Sigma CR150* Mobile Bearing A.L.P.S. System Modules* (Anatomic Fibula, Anatomic Elbow, Proximal Tibia) COUGAR LS Lateral Cage ScoliScore AIS Prognostic Test* GRYPHON BR ANCHOR NEXTRA System ORBIT GALAXY Detachable Embolic Coil* Diabetes Care ONETOUCH Ping (Canada) Diabetes High Accuracy Blood Glucose System (CE Mark) Cordis CARTO 3 V2 Navigation Technology (510(k) & CE Mark) PTA Balloons Next Generation (510(k) & CE Mark) THERMOCOOL SF Irrigated Catheter (Japan) DePuy RECLAIM Hip Revision Next Generation DVR Wrist Plate* Shoulder Fracture Platform CONFIDENCE Spinal Cement System LX TLIF Cage EXPEDIUM LX VIPER LX TLIF Cage VaprVue & Coolpulse 90 Diabetes Care Integrated Continuous Glucose Monitor/Insulin Pump (PMA & CE Mark) Diabetes High Accuracy Blood Glucose System Version 2 Cordis CARTO 3 V3 Navigation Technology (510(k) & CE Mark) THERMOCOOL SMARTTouch Contact Force Catheter (PMA & Japan) INCRAFT AAA Stent Graft (CE Mark) PRESILLION Plus Bare Metal Stent (PMA) S.M.A.R.T. Stent for SFA (PMA Supp) PTCA Balloon Next Generation (PMA & CE Mark) DePuy Next Generation Knee System Bone Preserving Hip Stem New Poly Hip Bearings DVR Express WW Screw Platelet Rich Plasma System Cordis NEVO Coronary Stent (PMA & Japan) EXOSEAL VCD (Japan) INCRAFT AAA Stent Graft (PMA & Japan) Circular Ablation (PMA & CE Mark) Next Gen NEVO Coronary Stent (PMA & CE Mark) DePuy DeltaMotion Hip System* Hip Bearings Hip Resurfacing System Next Generation Hip System Next Generation Shoulder CAIS Cartilage Regeneration * U.S. submission only. Selective Highlights as of 6/3/10. Filings/approvals assumed to be in U.S. unless otherwise noted. This information is accurate as of the date hereof to the best of the Company s knowledge. Johnson & Johnson assumes no obligation to update this information

21 MD&D Pipeline Highlights Ethicon, EES, OCD, Vision Care Pending Approved/Cleared Planned Submissions Planned Submissions Planned Submissions Ethicon SURGIFLO with Integrated Thrombin Kit (EU) DERMABOND Topical Skin Adhesive New Formulation Ethicon PROCEED Ventral Patch (EU) PDS Plus Antibacterial (polydioxanone) Suture (EU) PDS Flexible Plates (U.S. & EU) SURGIFLO with Integrated Thrombin Kit NUVANCE Facial Rejuvenation System (EU) PREVELLE Lift Dermal Filler (EU) ETHICON SECURESTRAP 5mm Strap Fixation Device ETHICON PHYSIOMESH Flexible Composite Mesh MENTOR Sensitive Anatomical Gel (EU) GYNECARE MORCELLEX Re-Launch GYNECARE PROSIMA Pelvic Floor Repair System GYNECARE TVT EXACT Continence System ETHICON OMNEX Surgical Sealant Ethicon Endo Echelon Flex 60mm Stapler ENSEAL Advanced Bipolar Shears Ethicon Endo-Surgery LINEAR CUTTER and Selectable Cartridges/Reloads Curved & Straight Intraluminal Staplers HARMONIC FOCUS Long Curved Shears ECHELON FLEX 45mm Stapler HARMONIC ACE Curved Shears with Ergo Handle (ACE45E) SEDASYS System (Canada & EU) OCD VITROS 5600 System + VITROS 3600 System VITROS Assays CELLEX Photopheresis System ORTHO VERSEIA Pipettor Vision Care 1-DAY ACUVUE MOIST for ASTIGMATISM 1-Day Acuvue TruEye Ethicon EVERPOINT Cardiovascular Needles Fibrin Pad (BLA) GYNECARE TVT ABBREVO Continence System GYNECARE V-Support Treatment Project Acclarent CYCLOPS Multi-Angle Endoscope Acclarent RELIEVA LUMA II Catheter Ethicon Endo ENSEAL Curved Open Shears HARMONIC /ENSEAL Combo Generator Endopath XCEL 5mm with OPTIVIEW Technology HARMONIC SYNERGY Combination Hook Blade STERRAD Solution Expansion OCD ORTHO VERSEIA Pipettor Assays New VITROS Assays: - Intact parathyroid hormone - Hepatitis B e-antigen and antibody VITROS 4600 System 1 Vision Care Anti-allergy drug with a contact lens Ethicon Fibrin Pad (EU) VICRYL RAPIDE Plus Suture GYNECARE SUI Sling Next Generation PurTox Highly Purified Botulinum Neurotoxin Ethicon Endo ECHELON Next Gen Device ENSEAL Next Gen Bipolar Lap Shears HARMONIC Next Gen Ortho HARMONIC Next Gen Plastics STERRAD Solution Expansion GLOSAIR Area Decontamination Solution OCD New VITROS Assays - HIV Combo 2 - Prostate-specific antigen 2 (PSA and Free PSA) - Syphilis Ethicon ETHICON Next Generation Wound Closure Project Mentor Becker Round Adjustable Gel GYNECARE Next Generation Pelvic Floor Repair Project Ethicon Endo Metabolics Next Gen MIS Next Gen Energy Solutions Next Gen Stapling STERRAD Solution Expansion Next Gen High-Level Disinfection OCD New VITROS Assay: Vitamin D VITROS 5300 System Transfusion Medicine Platform CELLEX System: Crohn s Disease and Graft-versus-host disease Advanced Cellular Diagnostics Molecular Diagnostics Next Generation: Circulating Tumor Cell Platform Selective Highlights as of 6/3/10. Filings/approvals assumed to be in U.S. unless otherwise noted. This information is accurate as of the date hereof to the best of the Company s knowledge. Johnson & Johnson assumes no obligation to update this information 1 Regulatory submission based on FDA filing for current platforms 2 PMA + VITROS 5600 System approved 10/08; VITROS 3600 System approved 12/08; Both launched 2009

22 Strengthen Global Presence BRIC Markets Growing 2-3x Overall Market MARKET SIZE CAGR MD&D BRIC Market $7.2 Billion 13% Brazil $2.2 Billion 9% Russia $1.0 Billion 13% India $1.0 Billion 14% China $3.0 Billion 15% *Data source: Internal Estimates and based on markets Johnson & Johnson competes in and is not reflective of the entire MD&D market; Constant Dollars

23 Strengthen Global Presence Developed Markets Continue to drive growth in U.S., Europe, and Japan Emerging Markets Globalize current products Improve access and affordability via market-appropriate products Expand professional education activities Gain market insights via local R&D and manufacturing

24 An Experienced Team of Leaders The leaders of our seven MD&D franchises have Cross-franchise experience within MD&D Cross-sector experience across Johnson & Johnson Experience outside the U.S. Experience outside Johnson & Johnson Michael Sneed Vision Care Michel Paul Diabetes Care Nicholas Valeriani Ortho Clinical Diagnostics Michael Mahoney DePuy Seth Fischer Cordis Gary Pruden Ethicon Karen Licitra Ethicon Endo-Surgery

25 MD&D: Well Positioned for Growth Strong track record of performance Favorable demographics and significant unmet needs Market-leading franchises with strong current products and robust pipelines Broad technology, scientific, and regulatory expertise Global infrastructure and capabilities Exceptional financial profile Talented, experienced, passionate people

26